Imat 400mg Tablet

The human body reacts differently to Imat 400 mg Tablet. Responses or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the side effects of Imat 400 mg Tablet are mentioned below:

• Muscle cramps
  
• Musculoskeletal pain (bones, muscles, joints)
  
• Rash / skin rash
  
• Bleeding / hemorrhage
  
• Breathing problems
  
• Cough
  
• Dizziness
  
• Weight gain / increased weight
  
• Edema (swelling in face, legs, ankles, feet, or body)
  
• Nausea
  
• Vomiting
  
• Diarrhea
  
• Fatigue / tiredness
  
• Abdominal pain
  
• Dry eyes
  
• Night sweats
  
• Headache
  
• Inflammation in the nose
  
• Fever
  
• Insomnia / lack of sleep
  
• Decreased red and white blood cell counts
  
• Heart failure
  
• Gastrointestinal disorders
  
• Hypothyroidism
  
• Liver failure

• Take the dose of Imat 400 mg tablet as per your healthcare provider’s prescription.
• Do not stop taking the medicine suddenly unless your doctor tells you to.
• This medicine is given under the strict supervision of a doctor. Do not self-administer.
• The medication is usually taken once daily with food and plenty of water, without chewing or crushing the tablet.
  

• Imat 400 mg Tablet is an anti-cancer medication that inhibits the proliferation of BCR-ABL tyrosine kinase, a protein enzyme.
• This enzyme helps cancer cells multiply and is responsible for the abnormal proliferation of cancer cells.
• Imat 400 mg tablet also induces apoptosis (programmed cell death) in BCR-ABL-positive cells (cancer cells).
  

•  I. Iacobucci et al. (2023). Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients. J Clin Oncol 25, 7041-7041. - https://www.researchgate.net/publication/339766404_Five-year_followup_results_of_imatinib_400_mg_in_late_chronic_phase_chronic_myeloid_leukemia_CML_patients
  
• Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE. (2024). Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 31(10):2224-32. - https://pubmed.ncbi.nlm.nih.gov/19922893/
  
• Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. (2024). A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120(19):3898-905.
  
• Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. (2025). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 362(24):2260-70 - https://pubmed.ncbi.nlm.nih.gov/20525995/
  
• Midha KK, Rawson MJ, Hubbard JW. (2025). The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 43(10):485-98.
  
• Druker BJ,Guilhot F,O'Brien SG, et al. (2024). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355: 2408-2417.
  
• O'Brien SG,Guilhot F,Larson RA, et al. (2023).  Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J 348: 994-1004.​​